Activation of αIIbβ3 is a sufficient but also an imperative prerequisite to activate α2β1 on platelets

Gerlinde R. Van de Walle¹, Anne Schoolmeester¹, Brecht F. Iserbyt¹, Judith M.E.M. Cosemans², Johan W.M. Heemskerk², Marc F. Hoylaerts³, Alan Nurden⁴, Karen Vanhoorelbeke¹ and Hans Deckmyn¹#

From the ¹Laboratory for Thrombosis Research, K.U. Leuven Campus Kortrijk, Kortrijk, Belgium; ²Departments of Biochemistry and Human Biology, CARIM, Maastricht University, The Netherlands; ³Center for Molecular and Vascular Biology, K.U. Leuven, Leuven, Belgium; ⁴Institut Fédératif N°4, Hopital Cardiologique, Pessac, France.

# Corresponding author: Prof. Dr. Hans Deckmyn, Laboratory for Thrombosis Research, K.U. Leuven Campus Kortrijk, E. Sabbelaan 53, B-8500 Kortrijk, Belgium; e-mail: hans.deckmyn@kuleuven-kortrijk.be

K.V. is a postdoctoral fellow of the ‘Fonds voor Wetenschappelijk Onderzoek (FWO), Vlaanderen’ Belgium. This study was supported by a Concerted Research Grant (GOA) from the University of Leuven (GOA/2004/09).
αIIbβ3 is required for α2β1 activation

Short title for running head: αIIbβ3 is required for α2β1 activation

Scientific section designation: Hemostasis, Thrombosis and Vascular Biology

Submit-accept-prepublish dates: 11/29/05-08/18/06-

Reprints: Prof. Dr. Hans Deckmyn, Laboratory for Thrombosis Research, K.U. Leuven Campus Kortrijk, E. Sabbelaan 53, B-8500 Kortrijk, Belgium; e-mail: hans.deckmyn@kulak.be

Keywords: integrin activation, α2β1, αIIbβ3, platelet, IAC-1

Statement of the authorship: G.V.d.W., A.S., J.M.E.M.C., B.I., K.V. participated in performing the research; G.V.d.W., A.S., K.V., J.W.M.H., M.H., H.D. participated in designing the research, providing relevant apparatus and in writing the paper. A.N. helped in the study of the Glanzmann’s patients. All authors checked the final version of the manuscript.
Platelet integrins $\alpha_2\beta_1$ and $\alpha_{IIb}\beta_3$ play critical roles in platelet adhesion and thrombus formation after vascular injury. On resting platelets, both integrins are in a low affinity state. However, agonist stimulation results in conformational changes that enable ligand binding that can be detected with conformation dependent monoclonal antibodies (mAbs). By using such conformation dependent mAbs, we could demonstrate that activation of integrin $\alpha_{IIb}\beta_3$ is not only sufficient, but also a prerequisite for $\alpha_2\beta_1$ activation. Compared to platelets in plasma, stimulation of washed platelets resulted in only a minor activation of $\alpha_2\beta_1$, as detected with the activation-sensitive mAb IAC-1. Addition of fibrinogen to stimulated washed platelets greatly potentiated activation of this integrin. Also, treatment of $\alpha_{IIb}\beta_3$ with the ligand-mimetic peptide RGDS, resulting in outside-in signaling, led to a powerful $\alpha_2\beta_1$ activation, even in the absence of overall platelet activation, involving tyrosine kinase activity but no protein kinase C activation. The absolute necessity of $\alpha_{IIb}\beta_3$ for proper $\alpha_2\beta_1$ activation on platelets was demonstrated by using the $\alpha_{IIb}\beta_3$ antagonist aggrastat, which was able to completely abolish $\alpha_2\beta_1$ activation, both under static and flow conditions. Additionally, analogous experiments with Glanzmann platelets, lacking $\alpha_{IIb}\beta_3$, confirmed the indispensability of $\alpha_{IIb}\beta_3$ for $\alpha_2\beta_1$ activation.
Introduction

Integrins are a large family of heterodimeric transmembrane receptors, each consisting of an α and β subunit, and are key effectors of cell growth, migration, differentiation and survival. Integrins possess the unique ability to signal across the plasma membrane in both directions and since most integrins are not constitutively active, they are expressed on the cell surface as low affinity receptors. When cells become activated, cytosolic proteins can bind to the cytoplasmic domains of integrins and as a consequence, the integrins are turned into their high affinity state ('inside-out' signaling). In a process called 'outside-in' signaling, ligand binding of integrins then again activates intracellular pathways via their cytoplasmic domains connected to the cytoskeleton and associated with several intracellular signaling molecules. Important signaling modulators necessary for the generation of outside-in signals are members of the Src family protein tyrosine kinases with c-Src as the initiating molecule due to its constitutive interaction with e.g. β3 integrins. Such outside-in signals also result in conformational alterations of the integrin (also designated integrin activation) and subsequently, these activated integrins can trigger another process of inside-out signaling. This integrin activation upon conformational changes is often defined as an increase in integrin ‘affinity’ for its ligand and has been the topic of many studies. In addition, cell activation also promotes clustering of integrins contributing to the ‘avidity’ or ‘valency’ regulation of ligand binding. So in their role as adhesion molecules, integrins signal across the plasma membrane in both directions and are able to switch from an inactive, low affinity conformation, to an active, high affinity conformation. Integrins can also interact with other receptors and this sort of ‘networking’ between membrane receptors can be defined as ‘cross-talk’. Numerous examples of cross-talk either between an integrin and another membrane...
receptor or between two integrins, resulting in inhibition or activation, have been reported in a variety of cell types \(^9\)-\(^{17}\).

On platelets, two major integrin receptors are expressed, both of which are involved in primary hemostasis. Integrin \(\alpha_{IIb}\beta3\) is the most abundant receptor with 40 to 80,000 copies per resting platelet, and acts as a major receptor for fibrinogen and other adhesive molecules \(^{18}\). Activation of \(\alpha_{IIb}\beta3\) enhances adhesion and leads to platelet-platelet interactions and aggregation \(^{19}\). Integrin \(\alpha2\beta1\), not uniquely expressed on platelets, is a less abundant receptor with around 2000 copies per platelet, and serves as a collagen receptor on platelets \(^{20}\). Together with the signaling collagen receptor GPVI, \(\alpha2\beta1\) is indispensable for stable adhesion of platelets to the extracellular matrix exposed after vascular injury \(^{21,22}\). The modulation of the integrin \(\alpha_{IIb}\beta3\) on platelets by other receptors has already been extensively studied. For instance, it has been reported that under flow, glycoprotein (GP) Ib binding to von Willebrand factor activates the integrin \(\alpha_{IIb}\beta3\), supporting localized platelet adhesion. Subsequently, a second level of \(\alpha_{IIb}\beta3\) activation, induced by e.g. ADP, is then necessary in order to allow platelet aggregation \(^{23}\). Furthermore, earlier work has suggested that \(\alpha_{IIb}\beta3\), together with \(\alpha2\beta1\), also becomes activated under flow following GPVI-induced platelet activation \(^{24}\). Since activation of both integrins is important during the process of primary hemostasis, it is appropriate to speculate that these two major integrin receptors may possibly modulate each other. Recently, our group has developed a monoclonal antibody (mAb), IAC-1, which recognizes an epitope of the \(\alpha2\) I-domain, hidden in the resting state and after outside stimulation of \(\alpha2\beta1\), but accessible when platelets are stimulated via inside-out signaling resulting in a fully activated form of \(\alpha2\beta1\) \(^{25,26}\). Moreover, since binding of this antibody does not require the presence of the receptor ligand, nor does it interfere with platelet collagen binding, it defines a new class of antibodies that is distinct from those belonging to the ‘ligand induced binding sites (LIBS)’ and the ‘ligand mimetic’ groups.
Here, we investigated whether the two major integrin receptors on platelets, αIIbβ3 and α2β1, can modulate each others activation state. By using the activation-sensitive mAb IAC-1, we report that activation of αIIbβ3 is necessary for proper α2β1 activation.

**Materials and Methods**

**Antibodies and proteins**

The mAb IAC-1, specific for the I-domain of fully activated α2β1, was isolated by our group as previously described and labeled with fluorescein isothiocyanate (FITC) according to the manufacturer’s instructions (Pierce, Rockford, IL). The anti-α2 I-domain mAbs Gi9 (FITC conjugated) and 15D7 were from Immunotech (Marseille, France) or made in-house respectively and both inhibit collagen-induced platelet aggregation. The anti-GPIb mAb 6B4 has been previously described, the anti-αIIbβ3 mAb AP2 and the anti-β3 mAb AP3 were from GTI (Waukesha, WI). The mAbs AK7 (anti-α2), phycoerythrin (PE) conjugated CD62P (anti-P-selectin), and FITC conjugated PAC-1 (anti-activated αIIbβ3) were from BD Bioscience (San Diego, CA). MOPC-21-FITC, an unrelated mouse anti-human IgG1 was from Sigma (Saint Louis, MO). Texas Red conjugated phalloidin was purchased from Molecular Probes (Eugene, OG) and polyclonal rabbit anti-mouse IgG-FITC was from Dako (Glostrup, Denmark).

Fibrinogen was purchased from Calbiochem (San Diego, CA), human collagen type III from Sigma and Horm collagen from Nycomed (Munich, Germany). Fibrinogen and collagen type III were FITC-labeled according to the manufacturer’s instructions (Pierce). The FITC labeling was performed in 50mM borate buffer (pH 8.5) after which excess of fluorescent dye was removed by overnight dialysis against phosphate buffered saline (PBS). As a
consequence, the collagen-FITC consisted mainly of reconstituted collagen fibrils, which in the presence of Mg$^{2+}$ specifically interact with $\alpha_2\beta_1$ and not GPVI.

**Inhibiting/activating agents and cells**

Convulxin (CVX; Kordia, Leiden, The Netherlands) and ADP (Sigma) were used as platelet activators. Dithiotreitol (DTT, Sigma) was used to activate $\alpha$IIb$\beta$3 on Chinese hamster ovary (CHO) cells. Antagonists of $\alpha$IIb$\beta$3 used were aggrastat, obtained from Merck Sharp & Dohme (Whitehouse Station, NJ) and RGDS from Sigma. Prostaglandin E$_1$ (PGE$_1$), staurosporin, genistein and Ro 31-8220 were all from Sigma. The Src kinase inhibitors PP2, PP1 and their control PP3 compound were from Calbiochem (Darmstadt, Germany).

Blood samples from healthy volunteers, free of antiplatelet agents for the last ten days, were collected on 3.13% trisodium citrate and platelet rich plasma (PRP) was prepared by centrifugation. Alternatively, blood was taken on acid citrate dextrose (ACD) and platelets were washed by several centrifugation steps in the presence of apyrase (75 mU/mL) and PGE1 (100 nM), essentially as previously described $^{26,28}$. Washed platelets were finally resuspended in Hepes/Tyrode (137mM NaHCO$_3$; 2mM KCl; 2mM MgCl$_2$; 0.3mM Na$_2$HPO$_4$; 12mM NaHCO$_3$; 5mM N-2-hydroxyethylpiperazine-N’-2-ethanesulfonic acid (Hepes); 0.01% (w/v) glucose; pH 7.4) supplemented with 0.3% BSA, at a concentration of 3x10$^5$/µl and allowed to rest for 20 min.

Where indicated, platelets from a previously characterized type I Glanzmann thrombasthenia patient $^{29}$ were isolated as described above. A second adult Glanzmann thrombasthenia patient with less than 10% surface-expressed $\alpha$IIb$\beta$3 in his platelets has not been previously reported. Blood was taken from the patients with informed consent and according to institutional guidelines.
CHO-dhfr\(^+\) cells and CHO-cells, expressing either human \(\alpha\)IIb\(\beta\)3 or \(\alpha\)2\(\beta\)1, both a kind gift from Dr. N. Kieffer (Laboratoire de Biologie et Physiologie Intégrée, Université du Luxembourg, Luxembourg)\(^30\), were cultured in Iscove’s Medium (Cambrex, Verviers, Belgium) supplemented with 10% (w/v) fetal calf serum, 1% (v/v) penicillin/streptomycin and 1% (v/v) L-glutamine. Cells were grown to confluency and routinely passaged after detachment using versene (Gibco).

**Flow cytometry**

Reaction mixtures of 5 µl PRP or washed platelets (in a total volume of 50 µl), activating agent (CVX at 50ng/mL or ADP 50µM final concentration), anti-P-selectin-PE (1/10 vol/vol) and FITC-labeled Gi9 (5µg/mL), FITC-labeled IAC-1 (10µg/mL) or FITC-labeled collagen (40µg/mL) in Hepes/Tyrode buffer were incubated for 30 min at room temperature (RT). When indicated, inhibiting agents were added before platelet activation. When using washed platelets, fibrinogen (0.1 to 5mg/mL) was added to the platelet suspensions as indicated. The reaction was stopped by adding 10 vol of 0.2% formaldehyde saline and a 1/10 dilution was analysed with an Epics XL-MCL flow cytometer (Becton Dickinson, Miami, FL). Data are presented as the mean value of fluorescence intensity (MFI) (5,000-10,000 cells per assay).

\(\alpha\)IIb\(\beta\)3-expressing CHO cells were washed by centrifugation and resuspended in aliquots of 0.5x10\(^6\) cells/mL in XL-medium (137mM NaCl; 5mM KCl; 1mM MgCl\(_2\); 5mM Hepes; 0.01% (w/v) glucose; pH 7.4) supplemented with or without 10mM DTT for 20min at RT. After incubation, cells were washed twice with an excess of XL-medium and either 5µg/mL PAC-1-FITC or 40µg/mL fibrinogen-FITC was added for 30min at RT. In other experiments, cells were stimulated with 10mM DTT, pre-incubated with 40µg/mL of unlabeled fibrinogen...
Van de Walle et al.  

αIIbβ3 is required for α2β1 activation for 30min at RT, and then incubated with 10μg/mL IAC-1-FITC for 30min at RT. After washing, cells were finally resuspended in 400μl of phosphate buffered saline (PBS), supplemented with 7-AAD (diluted 1/400, Molecular Probes). Cells were immediately analysed by flow cytometry. Where indicated, CHO cells expressing α2β1 were used for flow cytometric experiments in a similar manner.

Platelet adhesion under static conditions

Coverslips (18x18mm, Menzel-Glaser, Braunschweig, Germany) were coated with human collagen type III (25μg/mL in PBS) overnight at 4°C. Coverslips were blocked with 1% BSA and 0.1% glucose in Hepes/Tyrode buffer for 30 min at RT. Washed platelets were used at a concentration of 3x10^5/μl in Hepes/Tyrode buffer supplemented with 1mM MgCl₂ and pre-incubated for 30min in the presence or the absence of RGDS (1mM final concentration). Coverslips were washed twice with Hepes/Tyrode buffer before incubation with 300μl platelet suspension for 60min at RT. Coverslips were washed to remove unbound platelets and stained with IAC-1 and phalloidin-Texas Red as previously described. In parallel, coverslips were fixed with 0.5% glutaraldehyde and stained with May-Grünwald-Giemsa. Coverslips were examined with an inverted Nikon Eclipse TE200 microscope using standard emission and excitation filters. Platelet adhesion was quantified with a light microscope, at 400x magnification, connected to an Image Analyser (Lucia, Laboratory Imaging Ltd., Analis, Namur, Belgium), and expressed as the percentage of surface coverage. For each experiment, the mean ± SE of 10 images was determined.

Platelet adhesion under flow

Thrombus formation was measured under flow with blood that was perfused over a collagen surface as described before. Briefly, an area of 20x5 mm in the centre of a glass coverslip
was coated with fibrillar Horm type I collagen (200 µg/mL) for 20 min at 37°C. Platelet interaction with immobilized collagen was studied using a parallel plate flow chamber producing a wall shear rate of 1000 s$^{-1}$. Blood from healthy volunteers was collected on 40µM D-phenylalanyl-L-propyl-L-arginine chloromethyl ketone (PPACK, Calbiochem) and perfused for 4 minutes. After perfusion, the coverslips were rinsed with Hepes/Tyrode buffer, supplemented with 0.1% glucose, 0.1% BSA, 2 mM CaCl$_2$, and 1 U/mL heparin, containing IAC-1-FITC (10µg/mL), MOPC-21-FITC (5µg/mL) or Gi9-FITC (5µg/mL). Adhered platelets were visualized by phase contrast and fluorescence microscopy and the images were analysed for surface area coverage exactly as previously described 32.

Results

Activation of αIIbβ3 is sufficient to activate α2β1

Binding of fibrinogen to αIIbβ3 influences α2β1 activation

As previously demonstrated 25, stimulation of platelets in plasma with the strong platelet GPVI agonist convulxin (CVX) induces an activated conformation of α2β1 that can be readily recognized by the mAb IAC-1 (Figure 1A). However, an interesting observation was made when similar activation experiments were performed with washed platelets. In contrast to CVX-stimulated platelets present in plasma, IAC-1 bound only moderately to α2β1 present on CVX-stimulated washed platelets. This difference was not donor dependent and was statistically significant (p < 0.01, n = 3, Figure 1A). The presence of plasma was not responsible for a different degree of platelet activation, since CVX stimulation resulted in either case in a similar P-selectin exposure, indicating equal platelet granule secretion (Figure 1B). In addition, the binding of the control anti- α2 I-domain mAb Gi9 was not notably
altered (data not shown), proving (i) that the level of surface exposure of α2β1 was not different in both conditions and (ii) that the increased IAC-1 binding to platelets in plasma is most likely not due to trapping of the antibody by micro-aggregate formation. All experiments were carried out at the optimal concentration of fluorescent IAC-1 antibody and maximal doses of agonist, and similar results were seen when platelets were stimulated with lower agonist doses (data not shown). Similar, but less strong, activating effects on IAC-1 binding were seen when platelets were stimulated with ADP (data not shown).

The responsible driving force for the higher binding of IAC-1 to activated platelets in plasma compared to washed platelets was next investigated. In view of the known networking between integrins, we hypothesized that fibrinogen binding to αIIbβ3 on activated platelets could be required for optimal IAC-1 binding to α2β1 and, thus, optimal activation of this integrin. Addition of fibrinogen to CVX-stimulated washed platelets indeed dose-dependently increased α2β1 activation (Figure 1A) with higher levels of exogenous fibrinogen (1 to 5mg/ml) even resulting in more IAC-1 binding than what was seen in plasma. In contrast, fibrinogen did not influence the binding of the control anti-α2β1 mAb Gi9 (not shown) nor the exposure of P-selectin (p > 0.5, n = 3, Figure 1B), indicating that the increase in α2β1 activation is at least in part a consequence of fibrinogen binding to αIIbβ3.

Another explanation for the increased IAC-1 binding in the presence of fibrinogen could be that this mAb in addition would recognize an epitope on αIIbβ3-bound fibrinogen on platelets, since it has been described previously that anti-α2 mAbs may cross-react with RGD-dependent epitopes in fibrinogen. To analyse this, CHO cells expressing human αIIbβ3 were treated with DTT to bring this integrin in an activated conformation, after which purified fibrinogen was added and IAC-1 binding was determined. The complex fibrinogen bound to the activated αIIbβ3 on CHO cells, failed to bind IAC-1, demonstrating
that bound fibrinogen and ligand occupied activated αIIbβ3 do not contain an epitope recognized by IAC-1 (data not shown).

*αIIbβ3 is required for α2β1 activation*

A conformational change in αIIbβ3 induces a direct signaling to α2β1

The results thus far suggest that αIIbβ3 activation evoked by stimulation of platelet receptors such as GPVI, leads to subsequent activation of α2β1 via an outside-in signaling mechanism of αIIbβ3. Next, we investigated whether a conformational change in αIIbβ3 per se could influence the activation state of α2β1, independent of other platelet agonists. Therefore, we incubated platelets with the small peptide RGDS, known to bind to αIIbβ3 on non-activated platelets and to provoke conformational changes in both the αIIb and β3 subunit. Remarkably, addition of 1mM RGDS peptide to washed platelets stimulated the binding of fluorescent IAC-1 and collagen to a comparable degree as stimulation in the presence of the strong platelet agonist CVX and fibrinogen (p < 0.005, n = 6; Figure 2A). In this case, the α2β1 activation was not accompanied by P-selectin exposure, indicating that RGDS did not cause an overall platelet activation with secretion responses (Figure 2A). To demonstrate that RGDS has no direct effect on activation of α2β1, CHO-cells expressing human α2β1 were incubated with 1mM RGDS and IAC-1 binding was determined. These RGDS-triggered CHO-cells failed to bind IAC-1 confirming that α2β1 is not an RGD sensitive integrin (data not shown). In contrast, IAC-1 binding to these α2β1-expressing CHO cells was readily achieved by stimulation with a cell permeable α2-cytosolic peptide, as recently described. Similar experiments with the peptide-mimetic antagonist aggrastat, also known to bind αIIbβ3 on non-activated platelets and to induce a conformational change in the αIIb, but not the β3 subunit of αIIbβ3, did not result in IAC-1 binding, collagen binding or P-selectin exposure (Figure 2A). Binding of RGDS and aggrastat to αIIbβ3 was specific since
binding of PAC-1, which competes for the same binding site on αIIbβ3 \(^{40}\), was almost completely abolished (data not shown).

To investigate if the cellular pathway responsible for the observed signaling from αIIbβ3 to α2β1 is similar to the pathways described for integrin signaling, washed platelets were incubated with RGDS and a chemical inhibitor of signaling pathways. Since incubation of the RGDS-treated platelets with PGE\(_1\) (5µM fc), which elevates cAMP and thereby antagonizes many platelet processes, did not influence the degree of RGDS-induced α2β1 activation (unaltered IAC-1 binding) \((p>0.5, n=4, \text{Figure 2B})\), all further experiments were performed in the presence of PGE\(_1\) to exclude additional general activation effects. The proper working of PGE\(_1\) was demonstrated by adding PGE\(_1\) to CVX-stimulated platelets, which resulted in a significant decrease of IAC-1 binding \((p<0.5, n=3, \text{Figure 2B})\). The IAC-1 binding on RGDS-triggered washed platelets was significantly reduced by staurosporin (2µM), a broad spectrum inhibitor of serine-threonine protein kinases and also able to inhibit tyrosine phosphorylation. Addition of the general tyrosine kinase inhibitor genistein (50µg/mL) also decreased IAC-1 binding \((p<0.05, n=3, \text{Figure 2C})\) in contrast to the protein kinase C inhibitor Ro 31-8220 (10µM) \((p>0.5, n=4, \text{Figure 2C})\). The specific Src kinase inhibitor PP-2 (10µM) however, did not influence IAC-1 binding to RGDS-triggered platelets \((p>0.5, n=3, \text{Figure 2C})\). Using another Src kinase inhibitor, PP1 (10µM), gave similar results (data not shown). All inhibitors used were active at their respective concentration, as determined by a significant decrease in PAC-1 binding of ADP-stimulated platelets (data not shown).

Besides in suspension, RGDS was also able to induce IAC-1 binding under static adhesion conditions. Washed platelets in the presence of MgCl\(_2\) that were added to a collagen type III surface did adhere, but this did not result in visually detectable levels of IAC-1 binding, indicating absence of major α2β1 activation on the adhered platelets in the absence of fibrinogen (Figure 3). However, pre-incubation with RGDS for 30min resulted in (i) a
significant increase in number of adhered platelets to the collagen and (ii) a clearly positive IAC-1 staining of the adhered platelets (Figure 3). The control anti-α2 mAb AK7 gave similar fluorescence signals of the platelets, independent of RGDS addition (Figure 3A). The adhesion of platelets to coated collagen was α2β1-specific, since addition of the anti-α2 mAb 15D7 almost completely abolished platelet adhesion (data not shown). All together, these results demonstrate that activation of αIIbβ3, induced by a conformational change, can directly activate α2β1, resulting in collagen binding of platelets in suspension and more binding to collagen of platelets in adhesion.

**Activation of αIIbβ3 is a prerequisite to activate α2β1**

*Inhibition of fibrinogen binding to αIIbβ3 influences α2β1 activation in suspension*

To further substantiate the importance of αIIbβ3 activation for proper activation of α2β1, experiments were performed with platelets in plasma in the presence of aggrastat, an αIIbβ3 antagonist which blocks the binding of fibrinogen. Addition of aggrastat (1µg/mL) greatly reduced the binding of IAC-1 to CVX-stimulated platelets and thus α2β1 activation, by more than 90% (p < 0.01, n = 4; Figure 4A). In addition, aggrastat also inhibited the binding of α2β1 on platelets to fluorescent monomeric collagen (Figure 4A), confirming the importance of fibrinogen binding to activated αIIbβ3 for the adhesive properties of α2β1. The reduced IAC-1 binding with aggrastat was not due to a decreased platelet activation, as the exposure of P-selectin was not significantly altered in the presence of the αIIbβ3-blocker (p > 0.5, n = 4; Figure 4A). Similar results were obtained with Reopro®, another αIIbβ3 antagonist. As a control, no binding of Reopro® to human α2β1-expressing CHO-cells could be observed by flow cytometry (not shown), excluding the possibility of a direct blocking of α2β1 by αIIbβ3.
Van de Walle et al.  

\(\alpha_{IIb}\beta_3\) is required for \(\alpha_2\beta_1\) activation

antagonists. Similar results at low platelet concentrations further excluded the possibility that formation of (micro-) aggregates under non-stirring conditions interfered with IAC-1 binding (data not shown). Interestingly, the reduction in IAC-1 binding to \(\alpha_2\beta_1\) on CVX-stimulated platelets in plasma where \(\alpha_{IIb}\beta_3\) is blocked by aggrastat (Figure 4A), was notably lower than the observed IAC-1 binding to \(\alpha_2\beta_1\) on CVX-stimulated washed platelets (Figure 1A). This suggests that autocrine fibrinogen, present in platelet \(\alpha\)-granules (about 1mg fibrinogen/10\(^{10}\) platelets) and released upon platelet activation \(^4\(^1\), contributes to \(\alpha_{IIb}\beta_3\)-mediated IAC-1 binding to washed platelets.

Inhibition of fibrinogen binding to \(\alpha_{IIb}\beta_3\) influences \(\alpha_2\beta_1\) activation under flow conditions

The necessity of \(\alpha_{IIb}\beta_3\) activation for the activation state of \(\alpha_2\beta_1\) was also studied under dynamic flow conditions, representing a more physiological condition of platelet activation during thrombus formation \(^4\(^2\). The \(\alpha_{IIb}\beta_3\) antagonist aggrastat was again used to inhibit fibrinogen binding to platelet \(\alpha_{IIb}\beta_3\) in whole blood. Perfusion of the blood over a collagen surface at 1000 s\(^{-1}\) resulted in platelet adhesion and aggregate formation with a surface coverage of 18.0 ± 2.2% after 4 min of perfusion, as measured by phase contrast microscopy (Figure 5A). These aggregates stained positive for IAC-1 binding with a surface coverage measured by fluorescence microscopy of 16.4 ± 5.5%. Treatment with the \(\alpha_{IIb}\beta_3\)-antagonist aggrastat completely inhibited aggregate formation, although still many single platelets adhered, diffusely spread over the collagen surface (Figure 5A). IAC-1 binding to these platelets was significantly decreased by more than 80% (\(p < 0.001\), \(n = 5\); Figure 5B). Staining of the adherent platelets with an unrelated mouse anti-human IgG MOPC-21 did not result in a fluorescence signal. However, staining with the anti \(\alpha_2\) I-domain mAb Gi9 resulted in fluorescent staining of the platelets, regardless of the presence or absence of aggrastat, indicating that the detection system used was sensitive enough to visualize single platelets.
(Figure 5A). These experiments under flow conditions also demonstrate that inhibition of ligand binding to $\alpha$IIb$\beta$3 prevented activation of $\alpha$2$\beta$1.

**Absence of $\alpha$IIb$\beta$3 does not result in $\alpha$2$\beta$1 activation**

Finally, we wanted to prove that activation of $\alpha$IIb$\beta$3 is a prerequisite for proper activation of $\alpha$2$\beta$1 and therefore stimulated platelet rich plasma obtained from a patient with type I Glanzmann’s thrombasthenia, with no expression of $\alpha$IIb$\beta$3 on the cell surface $^{29}$, and determined IAC-1 and collagen binding. First, we checked for $\alpha$2$\beta$1 expression and as shown in Figure 6A, $\alpha$2$\beta$1 was expressed in similar amounts on platelets of the Glanzmann patient compared to those of the control. The absence of binding of the anti-$\alpha$IIb$\beta$3 mAb AP2 confirmed the Glanzmann phenotype, and the residual binding of the anti-$\beta$3 mAb AP3 has been described previously for this patient, since these platelets normally express the vitronectin receptor $\alpha$V$\beta$3 $^{29,43}$. When the Glanzmann platelets were stimulated with CVX, no IAC-1 binding nor collagen binding could be observed, in contrast to control platelets (Figure 6B). Stimulation of the Glanzmann platelets did not result in PAC-1 binding as expected and general platelet activation, detected by P-selectin exposure, was comparable to that of control platelets (Figure 6B). Similar results were observed after stimulation with ADP and with platelets from another Glanzmann patient (data not shown). These experiments with Glanzmann platelets demonstrate that proper $\alpha$2$\beta$1 activation on platelets cannot occur in the absence of $\alpha$IIb$\beta$3 and therefore reveal the absolute requirement of $\alpha$IIb$\beta$3 activation for activation of $\alpha$2$\beta$1.
Discussion

We previously characterized the mAb IAC-1 as an antibody specific for the $\alpha_2$ I-domain on fully activated integrin $\alpha_2\beta_1^{25,26}$. Here we have used this novel antibody to demonstrate that ligand binding to integrin $\alpha$IIb$\beta_3$ is a key regulator of $\alpha_2\beta_1$ activation. First, a significant reduction in IAC-1 binding to $\alpha_2\beta_1$ was observed when working with washed stimulated platelets, where plasma proteins like fibrinogen, are absent. Second, this low IAC-1 binding to washed stimulated platelets could be restored upon supplementation with purified fibrinogen. Third, blockage of the fibrinogen binding to $\alpha$IIb$\beta_3$ by aggrastat dramatically decreased IAC-1 binding to $\alpha_2\beta_1$, both under static and flow conditions. Fourth, addition of the $\alpha$IIb$\beta_3$-specific peptide RGDS induced IAC-1 binding to $\alpha_2\beta_1$ on resting platelets to a comparable degree as stimulation of platelets with CVX in the presence of fibrinogen, but without general platelet activation. Fifth, no IAC-1 binding to $\alpha_2\beta_1$ on Glanzmann platelets, with no $\alpha$IIb$\beta_3$ expression on the surface, was observed upon platelet stimulation. All these data suggest that stimulation of $\alpha$IIb$\beta_3$ is indispensable for the activation of the collagen-binding integrin $\alpha_2\beta_1$.

Activation of $\alpha$IIb$\beta_3$ upon cellular activation (inside-out signaling) or by binding to its ligand fibrinogen induces a conformational change in $\alpha$IIb$\beta_3$ and leads to outside-in signaling, resulting in tyrosine kinase activity, $\text{Ca}^{2+}$ responses, cytoskeletal reorganization and pseudopod formation $^{3,5,44-46}$. In addition, fibrinogen causes $\alpha$IIb$\beta_3$ clustering which also triggers signaling pathways, most likely by concentrating intracellular integrin-associated proteins $^{47,48}$. How and if monovalent $\alpha$IIb$\beta_3$ ligands like RGDS induce outside-in signaling of $\alpha$IIb$\beta_3$ has remained elusive. One study reported that in platelets, monovalent peptidomimetic $\alpha$IIb$\beta_3$-antagonists could not increase intracellular $\text{Ca}^{2+}$ concentrations, used
as a marker for outside-in signaling, although they induced LIBS epitopes\textsuperscript{39}. Here, platelet experiments with the monovalent \(\alpha\)IIb\(\beta\)3 ligand RGDS resulted in a significant IAC-1 binding, indicating that RGDS can mediate outside-in signaling of \(\alpha\)IIb\(\beta\)3, which results in activation of \(\alpha2\beta1\). Moreover, the IAC-1 binding induced upon RGDS addition was similar in degree as seen in platelets stimulated with the strong agonist CVX and fibrinogen, but clearly without evoking overall platelet activation as is known for RGDS. Similar experiments with another monovalent ligand, the \(\alpha\)IIb\(\beta\)3-antagonist aggrastat, did not result in IAC-1 binding. This is similar to the study of Honda \textit{et al.},\textsuperscript{39} where aggrastat was not able to increase intracellular Ca\textsuperscript{2+} concentrations in non-activated platelets. Since RGDS induces conformational changes in both the \(\alpha\)IIb and \(\beta\)3 subunit, whereas aggrastat results only in a conformational change of the \(\alpha\)IIb subunit\textsuperscript{36,39}, our results point out that a conformational change in the \(\beta\)3 subunit, but not in \(\alpha\)IIb, is a prerequisite for \(\alpha\)IIb\(\beta\)3-mediated outside-in signaling. This is consistent with previous reports, where it has been described that the cytoplasmic domain of the \(\beta\)3 subunit plays a critical role in \(\alpha\)IIb\(\beta\)3-mediated outside-in signaling\textsuperscript{49-51}.

When washed platelets were allowed to adhere to coated collagen type III under static conditions, some adhesion was observed but this was not accompanied by fluorescent IAC-1 staining, or in other words \(\alpha2\beta1\) activation. This \(\alpha2\beta1\)-dependent cell adhesion to coated collagen without IAC-1 binding has already been described for \(\alpha2\beta1\)-expressing CHO cells under static conditions and for platelet adhesion \textit{in vitro}\textsuperscript{24,26}. Here, treatment of the platelets with RGDS resulted in significant more adhesion of the platelets to collagen and this was accompanied by IAC-1 binding. This is also similar to our previous data, where direct inside-out stimulation of \(\alpha2\beta1\) by using a cell permeable \(\alpha2\) cytosolic peptide resulted both in enhanced adhesion and IAC-1 binding\textsuperscript{26}. 
αIIbβ3 is required for α2β1 activation

The observed direct signaling from αIIbβ3 to α2β1 upon RGDS addition involves tyrosine kinase activity, as shown by the sensitivity to genistein, however, we were not able to find evidence for the involvement of the major integrin signaling tyrosine kinase Src. Also, we could not observe a contribution of protein kinase C, but this has already been described for platelets where both αIIbβ3 and α2β1 activation can occur via PKC-dependent and – independent, cAMP-insensitive, pathways, depending on the agonist used. Hence, for the moment it remains elusive whether the signaling from αIIbβ3 to α2β1 will be similar to previously described integrin signaling pathways, or whether this signaling occurs via another, yet undescribed, pathway.

Linking the observations that ligand binding to αIIbβ3 results in α2β1 activation with the observation that blockage of αIIbβ3 activation can almost completely abolish IAC-1 binding, resulted in the hypothesis that αIIbβ3 is indispensable for activation of α2β1. To test this, platelets from patients with type I Glanzmann thrombasthenia, without any expression of αIIbβ3 on the cell surface, were isolated and stimulated with platelet agonists such as CVX and ADP. Stimulation of these platelets did not result in IAC-1 or collagen binding to α2β1 in contrast to wild type platelets. This confirms that αIIbβ3 activation is essential for proper activation of α2β1.

Lecut et al. demonstrated that the collagen receptor GPVI, along with autocrine ADP and thromboxane, mediates α2β1 and αIIbβ3 integrin activation during collagen-induced thrombus formation under flow. Under control conditions of a moderate high shear of 1000 s⁻¹, both PAC-1 (for activated αIIbβ3) and IAC-1 (for activated α2β1) binding was observed, whereas blockade of the platelet receptor GPVI reduced PAC-1 binding and thus αIIbβ3 activation. This reduction was accompanied by a reduced IAC-1 binding, indicating that also the activation of α2β1 was severely impaired. The observations in the present study now
suggest for the first time that the affinity regulation of \( \alpha_2\beta_1 \) and \( \alpha_{IIb}\beta_3 \) by GPVI during thrombus formation does not occur independently, but more in a two-step model: first, stimulation of GPVI activates the integrin \( \alpha_{IIb}\beta_3 \) and second, ligand binding to the activated \( \alpha_{IIb}\beta_3 \) will in turn activate the integrin \( \alpha_2\beta_1 \). Although the physiological importance of this two-step model of integrin activation during human platelet thrombus formation \textit{in vivo} is not yet known, we hypothesize that the two collagen receptors GPVI and \( \alpha_2\beta_1 \), the latter in an inactive or intermediate active conformation, are necessary for platelets to bind to exposed immobilized collagen upon vessel wall damage. GPVI will next activate \( \alpha_{IIb}\beta_3 \) which will result in platelet aggregation on the one hand and activation of \( \alpha_2\beta_1 \) to its fully activated conformation on the other hand. This fully activated conformation of \( \alpha_2\beta_1 \) may then reinforce the adhesion of the adhered platelets, which is in line with recent data showing that the fully active conformation of \( \alpha_2\beta_1 \) results in significantly more adhesion\(^{26}\). Moreover, in parallel with resting \( \alpha_{IIb}\beta_3 \) that is only able to bind to immobilised fibrinogen but requires activation to bind to soluble fibrinogen, also resting \( \alpha_2\beta_1 \) only can interact with its immobilized ligand and not with the soluble form. As however no soluble collagen is expected to be present physiologically, our results imply that the role of \( \alpha_2\beta_1 \) activation is to allow for faster platelet adherence and for platelet spreading: indeed activation of \( \alpha_2\beta_1 \) on CHO-cells allowed them to spread\(^{26}\), whereas it is known that Glanzmann’s platelets attach but do not spread on collagen\(^{55}\).

In summary, we here demonstrate for the first time that activation of \( \alpha_{IIb}\beta_3 \) is both a sufficient and required condition for full activation of \( \alpha_2\beta_1 \) on platelets, a process which may have physiological importance during platelet thrombus formation \textit{in vivo}.

\textbf{Acknowledgements}
The authors are grateful to Dr. N. Kieffer (Laboratoire de Biologie et Physiologie Intégrée, Université du Luxembourg, Luxembourg) for the αIIbβ3 and α2β1-expressing CHO cells and Dr. Paquita Nurden for obtaining the blood from the Glanzmann thrombasthenia patients. We also thank R. Combrié for analysing the data on the Glanzmann platelets.
Reference List


αIIbβ3 is required for α2β1 activation


αIIbβ3 is required for α2β1 activation


Figure Legends

Figure 1. IAC-1 binding to \( \alpha_2 \beta_1 \) on activated washed platelets is decreased compared to platelets activated in plasma and increased by binding of fibrinogen to \( \alpha_{IIb}\beta_3 \). Flow cytometric analysis of IAC-1 (A) or anti-P-selectin (B) binding to resting or CVX-stimulated platelets in plasma (PRP, white) or in buffer in the presence of increasing concentrations of fibrinogen (WP, black). All data are expressed as the mean ± SEM of at least 3 independent experiments. In all experiments, saturating concentrations of fluorescent antibodies were used.

Figure 2. Increased IAC-1 binding to \( \alpha_2 \beta_1 \) on RGDS-treated washed platelets and involvement of tyrosine kinases and actin in this signaling. (A) Flow cytometric experiments detecting IAC-1, collagen and anti-P-selectin binding to resting washed platelets (white), to RGDS-treated washed platelets (grey), to CVX-stimulated washed platelets in the presence of 100\( \mu \)g/mL fibrinogen (black) or to aggrastat-treated washed platelets (grey shaded). (B) Flow cytometric experiments of IAC-1 binding to RGDS- and CVX-stimulated platelets in the absence (white bar) or presence (grey bar) of PGE\(_1\) (5\( \mu \)M). (C) Flow cytometric experiments of IAC-1 binding to RGDS-triggered platelets incubated with 5\( \mu \)M PGE\(_1\) in the absence or presence of staurosporin (2\( \mu \)M), Ro 31-8220 (10\( \mu \)M), genistein (50\( \mu \)g/mL), or PP2 (10\( \mu \)M). All data are expressed as mean ± SEM of at least 3 independent experiments.

Figure 3. IAC-1 binding to \( \alpha_2 \beta_1 \) on RGDS-treated washed platelets under static adhesion conditions. Unstimulated or RGDS-treated washed platelets were allowed to adhere to immobilized collagen type III coated coverslips for 60min. After fixation and permeabilization, cells were incubated with phalloidin-Texas Red (200nM) to stain actin and
AK-7 (5µg/mL), followed by a 1/50 dilution of rabbit-anti-mouse IgG-FITC, to stain α2β1 or IAC-1-FITC (10µg/mL) to stain activated α2β1. Bars indicate 25µm.

Figure 4. Inhibition of fibrinogen binding to αIIbβ3 reduces IAC-1 binding to α2β1 on CVX-stimulated platelets in plasma. (A) Flow cytometric experiments with FITC-labeled IAC-1, FITC-labeled monomeric collagen and PE-labeled anti-P-selectin, binding to resting platelets (white) or to CVX-stimulated platelets in the absence (black) or presence (grey) of 1 µg/mL aggrastat. Data are expressed as the mean ± SEM of at least 3 independent experiments. (B) Representative tracings of the experiments depicted in A with the binding of FITC-labeled IAC-1 (left panel) and PE-labeled anti-P-selectin (right panel) to resting platelets (grey shaded) or to CVX-stimulated platelets in the absence (black line) or presence (grey line) of aggrastat. In all experiments, saturating concentrations of fluorescent antibodies were used.

Figure 5. Inhibition of fibrinogen binding to αIIbβ3 decreases IAC-1 binding to adhering platelets under flow conditions. Anticoagulated whole human blood was perfused over a collagen-coated surface at a wall shear rate of 1000 s⁻¹. Postperfusion was performed with either FITC-labeled MOPC-21 (5µg/mL), FITC-labeled Gi9 (5µg/mL) or FITC-labeled IAC-1 (10µg/mL) (A) Representative phase contrast (left panel) and fluorescence (right panels) microscopic images of adhered platelets after 4 minutes of perfusion in the presence (lower panel) or absence of aggrastat (upper panel). (B) Platelet adhesion in the presence or absence of aggrastat, determined as percentage of surface coverage. Data obtained from phase contrast images are in black; fluorescence data of IAC-1-FITC images are in white. Data are expressed as the mean ± SE of 10 images of at least 3 independent experiments. Bars indicate 25µm.
Figure 6. IAC-1 binding to α2β1 on CVX-stimulated platelets in plasma is not observed in the absence of αIIbβ3. (A) Flow cytometric analysis of membrane glycoprotein expression of the Glanzmann platelets. Control platelets in plasma (white bar) or platelets from a Glanzmann patient in plasma (grey bar) were incubated with AK-7 (anti-α2, 2μg/mL), AP2 (anti-αIibβ3, 5μg/mL), AP3 (anti-β3, 5μg/mL) or 6B4 (anti-GPIb, 2μg/mL), followed by a 1/10 dilution of rabbit-anti-mouse IgG-FITC. (B) Flow cytometric experiments detecting IAC-1, collagen, PAC-1 and anti-P-selectin binding to resting platelets (-) or CVX-stimulated platelets (+) of control (white bar) or Glanzmann patient (grey bar). Data are expressed as the mean ± SEM of at least 2 independent experiments on control platelets and one or two experiments on Glanzmann platelets.
Figure 1: Van de Walle et al.
αIIbβ3 is required for α2β1 activation

Figure 2: Van de Walle et al.
\[ \alpha_{IIb}\beta_3 \text{ is required for } \alpha_2\beta_1 \text{ activation} \]

**Figure 3: Van de Walle et al.**
αIIbβ3 is required for α2β1 activation

Figure 4: Van de Walle et al.
Figure 5: Van de Walle et al.
\( \alpha IIb \beta 3 \) is required for \( \alpha 2 \beta 1 \) activation

Figure 6: Van de Walle et al.